Patients Report Mouth Dryness as Key Sjögren's Concern
Johnson & Johnson's Phase 2 DAHLIAS study found mouth dryness is the symptom improvement patients care about most in Sjögren's disease.
Global Arthritis News
Arthritis in the world runs on clinical research, treatment advances and pain management, and coverage here follows all of it. Reporting focuses on joint health studies, prevalence data and new approaches to managing chronic conditions.
Recent news
November 6, 2026
Daratumumab Shows Kidney Response in Lupus PatientsA small phase 2 trial found the antibody therapy improved kidney function in most participants at 12 months, though relapses occurred later.
November 6, 2026
EU Expands Jyseleca Approval for Axial SpondyloarthritisThe European Commission has approved filgotinib for adults with active axial spondyloarthritis who respond inadequately to conventional therapy.
November 5, 2026
Ultrasound Nerve Procedure Eases Carpal TunnelA randomized trial found saline hydrodissection gave lasting relief for carpal tunnel syndrome patients who had not responded to conventional treatment.
November 4, 2026
Neutrophils in Arthritis and COVID-19 DivergeA study comparing neutrophil gene activity finds that rheumatoid arthritis and COVID-19 share few overlapping immune signals.
November 4, 2026
Shockwave Therapy Eases Frozen Shoulder PainA review of 189 studies compares treatments for frozen shoulder, a condition affecting around 5 per cent of people at some point in their lives.
November 4, 2026
Plant Compounds Show Promise Against Arthritis TargetComputer modeling identifies four phytochemicals that may inhibit JAK proteins involved in rheumatoid arthritis.
November 4, 2026
GEBRO, Spektus Pharma Partner on ActraFlexThe two companies signed a global commercialisation agreement for the twice-daily extended-release pain therapy ActraFlex.
November 3, 2026
Patient-Choice Trial Boosts Arthritis Treatment SatisfactionA multicenter randomized trial found rheumatoid arthritis patients who chose their own treatment reported greater satisfaction and fewer adverse events.
November 3, 2026
PHF2 Emerges as Brake on Bone-Breaking CellsResearchers report that the enzyme PHF2 restrains osteoclast formation by marking the transcription factor NFATc1 for degradation.
November 2, 2026
Risankizumab Shows Lower Drug Change Rate in Psoriatic ArthritisFinal 37-month VALUE study results compare drug change rates across biologic treatments for patients with psoriasis and psoriatic arthritis.
More in Arthritis
Global reporting spans clinical trials, pharmaceutical developments, joint health findings and chronic pain management strategies. It reaches every region and institution where medical research is conducted and patient care is provided. Joint health research often highlights the contrast between lifestyle interventions and medical or surgical options. The evolving understanding of autoimmune responses continues to change the way long-term care is structured.